Cytomegalovirus colitis in a burn patient

Jeff T. Gibbs, Madeline Zieger, Rajiv Sood

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The prevalence of cytomegalovirus in the burn population is high. However, its role in the clinical management of burn patients is still being defined. This report documents a 41-year-old man who developed cytomegalovirus (CMV) colitis after being admitted with a 72% burn. Before the administration of ganciclovir, the authors had difficulty controlling his quantitative wound cultures with serial debridements, topical agents, and systemic antibiotics for known pathogens, which led to graft loss. After the ganciclovir was given, his quantitative wound cultures improved without changing the authors' topical agents or systemic antibiotics and had improved graft take. Whether CMV infection alone contributed to an increased morbidity in this patient or the combination of bacteria/fungal infection with CMV led to a synergistic effect is still not clearly understood. CMV may have contributed to a dysfunction in his cell mediated immunity, which, in turn, lowered the bacterial and fungal load necessary to cause graft loss. Patients who continue to do poorly despite adequate treatment for known pathogens may need to be screened for CMV and treated.

Original languageEnglish (US)
Pages (from-to)e298-e300
JournalJournal of Burn Care and Research
Volume37
Issue number3
DOIs
StatePublished - 2016

Fingerprint

Colitis
Cytomegalovirus
Ganciclovir
Transplants
Anti-Bacterial Agents
Mycoses
Bacterial Load
Wounds and Injuries
Cytomegalovirus Infections
Debridement
Cellular Immunity
Morbidity
Bacteria
Population

ASJC Scopus subject areas

  • Emergency Medicine
  • Rehabilitation
  • Surgery

Cite this

Cytomegalovirus colitis in a burn patient. / Gibbs, Jeff T.; Zieger, Madeline; Sood, Rajiv.

In: Journal of Burn Care and Research, Vol. 37, No. 3, 2016, p. e298-e300.

Research output: Contribution to journalArticle

Gibbs, Jeff T. ; Zieger, Madeline ; Sood, Rajiv. / Cytomegalovirus colitis in a burn patient. In: Journal of Burn Care and Research. 2016 ; Vol. 37, No. 3. pp. e298-e300.
@article{5fbd182a80f24076a3d7ffedab827f95,
title = "Cytomegalovirus colitis in a burn patient",
abstract = "The prevalence of cytomegalovirus in the burn population is high. However, its role in the clinical management of burn patients is still being defined. This report documents a 41-year-old man who developed cytomegalovirus (CMV) colitis after being admitted with a 72{\%} burn. Before the administration of ganciclovir, the authors had difficulty controlling his quantitative wound cultures with serial debridements, topical agents, and systemic antibiotics for known pathogens, which led to graft loss. After the ganciclovir was given, his quantitative wound cultures improved without changing the authors' topical agents or systemic antibiotics and had improved graft take. Whether CMV infection alone contributed to an increased morbidity in this patient or the combination of bacteria/fungal infection with CMV led to a synergistic effect is still not clearly understood. CMV may have contributed to a dysfunction in his cell mediated immunity, which, in turn, lowered the bacterial and fungal load necessary to cause graft loss. Patients who continue to do poorly despite adequate treatment for known pathogens may need to be screened for CMV and treated.",
author = "Gibbs, {Jeff T.} and Madeline Zieger and Rajiv Sood",
year = "2016",
doi = "10.1097/BCR.0000000000000255",
language = "English (US)",
volume = "37",
pages = "e298--e300",
journal = "Journal of Burn Care and Research",
issn = "1559-047X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Cytomegalovirus colitis in a burn patient

AU - Gibbs, Jeff T.

AU - Zieger, Madeline

AU - Sood, Rajiv

PY - 2016

Y1 - 2016

N2 - The prevalence of cytomegalovirus in the burn population is high. However, its role in the clinical management of burn patients is still being defined. This report documents a 41-year-old man who developed cytomegalovirus (CMV) colitis after being admitted with a 72% burn. Before the administration of ganciclovir, the authors had difficulty controlling his quantitative wound cultures with serial debridements, topical agents, and systemic antibiotics for known pathogens, which led to graft loss. After the ganciclovir was given, his quantitative wound cultures improved without changing the authors' topical agents or systemic antibiotics and had improved graft take. Whether CMV infection alone contributed to an increased morbidity in this patient or the combination of bacteria/fungal infection with CMV led to a synergistic effect is still not clearly understood. CMV may have contributed to a dysfunction in his cell mediated immunity, which, in turn, lowered the bacterial and fungal load necessary to cause graft loss. Patients who continue to do poorly despite adequate treatment for known pathogens may need to be screened for CMV and treated.

AB - The prevalence of cytomegalovirus in the burn population is high. However, its role in the clinical management of burn patients is still being defined. This report documents a 41-year-old man who developed cytomegalovirus (CMV) colitis after being admitted with a 72% burn. Before the administration of ganciclovir, the authors had difficulty controlling his quantitative wound cultures with serial debridements, topical agents, and systemic antibiotics for known pathogens, which led to graft loss. After the ganciclovir was given, his quantitative wound cultures improved without changing the authors' topical agents or systemic antibiotics and had improved graft take. Whether CMV infection alone contributed to an increased morbidity in this patient or the combination of bacteria/fungal infection with CMV led to a synergistic effect is still not clearly understood. CMV may have contributed to a dysfunction in his cell mediated immunity, which, in turn, lowered the bacterial and fungal load necessary to cause graft loss. Patients who continue to do poorly despite adequate treatment for known pathogens may need to be screened for CMV and treated.

UR - http://www.scopus.com/inward/record.url?scp=84964969853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964969853&partnerID=8YFLogxK

U2 - 10.1097/BCR.0000000000000255

DO - 10.1097/BCR.0000000000000255

M3 - Article

VL - 37

SP - e298-e300

JO - Journal of Burn Care and Research

JF - Journal of Burn Care and Research

SN - 1559-047X

IS - 3

ER -